- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT00923520
A Phase 1, Dose Escalation Study of the Safety, Tolerability, and Pharmacokinetics of Intravenous Dimethane Sulfonate (DMS612) in Advanced Malignancies
A Phase 1, Dose Escalation Study of the Safety, Tolerability and Pharmacokinetics of Intravenous Dimethane Sulfonate (DMS612, NSC 281612) in Advanced Malignancies
Background:
- Dimethane sulfonate (DMS612) is an investigational drug that is being administered to humans for the first time in people with advanced tumors. More information on the maximum tolerated dose of DMS612 will help researchers identify whether the drug is suitable for use in treating certain kinds of cancer, particularly renal cell carcinoma.
Objectives:
- To determine the maximum tolerated dose of DMS612 (the highest dose that does not cause unacceptable side effects) and evaluate any side effects.
- To see if DMS612 has any effect on patients tumors through blood tests and laboratory studies.
- To learn how the body processes DMS612.
Eligibility:
- Patients 18 years of age and older who have been diagnosed with cancer that has not responded well to standard treatments.
Design:
- Pre-treatment evaluation visit to determine eligibility:
- Physical examination
- Blood and urine tests
- Chest X-ray; electrocardiogram; CAT scan of chest, abdomen, pelvis, and other areas of the body if needed
- Other possible tests, such as magnetic resonance imaging (MRI) or positron emission tomography (PET)
- Patients will receive one dose of DMS612 by intravenous infusion once a week for 3 weeks, followed by 1 week without the drug. Doses will be adjusted based on possible side effects and cancer response. The disease will be evaluated after three cycles of the drug.
- Evaluations during the treatment period:
- Physical examination and reviews of side effects.
- Blood draws to evaluate the effectiveness of the drug, and how it is processed by the body.
- CAT scan at the end of every two cycles (every 8 weeks).
- Other scans and imaging procedures as required by the study doctors.
Studie Overzicht
Toestand
Interventie / Behandeling
Gedetailleerde beschrijving
Background:
- The dimethane sulfonates are a group of agents that were identified as active against renal cell carcinoma in the NCI anticancer drug screen.
- In vitro studies showed that dimethane sulfonates have properties in common with alkylating agents, but are unlike conventional alkylators (such as nitrogen mustards, BCNU, or busulfan) in that they are active against renal cell carcinoma (RCC).
Objective:
Primary:
-To determine dose-limiting toxicity (DLT), MTD and recommended phase II dose (RPTD) of dimethane sulfonate (DMS612, NSC 281612) when administered by intravenous (IV) bolus on day 1 and 2 of a 21-day cycle.
Eligibility:
- Patients must have histologically confirmed solid tumor malignancy or lymphoma that is metastatic or unresectable and for which standard curative or palliative measures do not exist or are no longer effective.
- Any prior chemotherapy therapy is allowed in this protocol. No more than 2 prior cytotoxic chemotherapy regimens are allowed.
- Age greater than or equal to 18 years. Because no dosing or adverse event data are currently available on the use of Dimethane sulfonate in patients less than 18 years of age, children are excluded from this study but will be eligible for future pediatric phase 1 single-agent trials.
- ECOG performance status 0-2 (Karnofsky greater than or equal to 60%,).
- Life expectancy of 3 months or greater.
- Patients must have acceptable organ and marrow function as defined below: leukocytes greater than or equal to 3,000/mcL, absolute neutrophil count greater than or equal to 1,500/mm(3), platelets greater than or equal to 100,000/, mm(3) total bilirubin within normal institutional limits, AST(SGOT)/ALT(SGPT), less than or equal to 2.5 times the institutional upper limit of normal, creatinine within normal institutional limits or creatinine clearance greater than 50mL/min for patients with creatinine levels above institutional normal.
Design:
This is a Phase I study of the safety, pharmacokinetics, pharmacodynamics and antitumor activity of IV DMS612, NSC 281612, designed as an open-label, dose-escalation study to determine the RPTD of DMS612, NSC 281612 based on safety and pharmacokinetics. With the 02/09/2015 amendment and change in schedule to evaluate a day 1 and 2 dosing every 6 weeks the following schema will be used:
Dose Level Dose of NSC 281612 Escalation (%)
1 3.5 mg/m2 on Day 1 and 2 -33
4A 4.5 mg/m2 on Day 1 and 2 ---
5A 6 mg/m2 on Day 1 and 2 33
6A 8 mg/m2 on Day 1 and 2 67
7A 10.5 mg/m2 on Day 1 and 2 33
7B 10.5 mg/m2 on Day 1 and 2 q 6 weeks ---
8A 14 mg/m2 on Day 1 and 2 33
8B 14 mg/m2 on Day 1 and 2 q 6 weeks --
Studietype
Inschrijving (Werkelijk)
Fase
- Fase 1
Contacten en locaties
Studie Locaties
-
-
Maryland
-
Bethesda, Maryland, Verenigde Staten, 20892
- National Institutes of Health Clinical Center, 9000 Rockville Pike
-
-
Pennsylvania
-
Hershey, Pennsylvania, Verenigde Staten, 17033
- Hershey Medical Center
-
Pittsburgh, Pennsylvania, Verenigde Staten, 15261
- University of Pittsburgh
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Beschrijving
- INCLUSION CRITERIA:
- Patients must have histologically confirmed solid tumor malignancy or lymphoma that is metastatic or unresectable and for which effective therapy does not exist or is no longer effective.
- Any prior chemotherapy therapy is allowed in this protocol. No more than 2 prior cytotoxic chemotherapy regimens are allowed for eligibility. Non-myelotoxic therapies such as sunitinib and sorafenib or everolimus are not considered "cytotoxic chemotherapies".Patients must be greater than or equal to 4 weeks from prior radiation or cytotoxic chemotherapy, except greater than or equal to 6 weeks for mitomycin C and nitrosoureas; greater than or equal to 2 weeks from hormonal therapy; greater than or equal to 4 weeks from prior experimental therapy; greater than or equal to 4 weeks from monoclonal antibody therapy (cetuximab, bevacizumab), greater than or equal to 2 weeks from sorafenib, sunitinib or temsirolimus and greater than or equal to 8 weeks from prior UCN01 treatment. Patients with prostate cancer may continue ongoing LHRH agonist therapy. Patients with bone metastases or hypercalcemia who began intravenous bisphosphonate treatment prior to study entry may continue this treatment.
- Age greater than or equal to 18 years. Because no dosing or adverse event data are currently available on the use of dimethane sulfonate in patients less than 18 years of age, children are excluded from this study but will be eligible for future pediatric phase 1 single-agent trials.
- ECOG performance status 0-2 (Karnofsky greater than or equal to 60%,).
- Life expectancy of 3 months or greater.
Patients must have acceptable organ and marrow function as defined below:
- leukocytes greater than or equal to 3,000/mm(3)
- absolute neutrophil count greater than or equal to 1,500/ mm(3)
- platelets greater than or equal to 100,000/ mm(3)
- total bilirubin within normal institutional limits
- AST(SGOT)/ALT(SGPT) less than or equal to 2.5 times institutional upper limit of normal
- creatinine within normal institutional limits OR
- 24 hour urine creatinine clearance greater than 50 mL/min/1.73 m(2) for patients with creatinine levels above institutional normal (may use creatinine clearance Cockcroft-Gault Equation).
- The effects of dimethane sulfonate on the developing human fetus are unknown. For this reason and because alkylating agents are known to be teratogenic, women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for at least 3 months after study participation. Should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately.
- Ability to understand and the willingness to sign a written informed consent document.
- Willing to comply with study procedures and follow-up.
EXCLUSION CRITERIA:
- Patients who have not recovered (CTC less than or equal to grade I) from adverse events due to prior treatments
- Patients may not have received more than 2 prior cytotoxic regimens.
- Patients may not be receiving any other investigational agent with therapeutic anticancer intent.
- Patients with history of CNS metastasis, unless control has been achieved with either radiation or surgical resection at least 3 months prior to enrollment on study.
- Patients who have had radiation to the pelvis or other bone marrow-bearing sites will be considered on a case by case basis and may be excluded if the bone marrow reserve is not considered adequate (greater than 25% of bone marrow irradiated).
- Uncontrolled medical illness including, but not limited to, ongoing or active infection, chronic or acute hepatitis, renal failure, symptomatic congestive heart failure, myocardial infarction within the last 6 months, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.
- Pregnant women are excluded from this study because DMS612 is likely to have toxicities similar to the alklyating agents with the potential for teratogenic or abortifacient effects. Because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with DMS612, breastfeeding should be discontinued if the mother is treated with DMS612.
- HIV-positive patients on combination antiretroviral therapy are ineligible because of the potential for pharmacokinetic interactions with DMS612. In addition, these patients are at increased risk of lethal infections when treated with marrow-suppressive therapy. Appropriate studies will be undertaken in patients receiving combination antiretroviral therapy when indicated.
- Patients are not eligible for the study if taking cytochrome P450-inducing anticonvulsants. This applies to patients with brain metastasis or those taking anticonvulsant for another reason (ie. Epilepsy).
- Patients diagnosed with alcoholism may not be treated with disulfiram.
- Patients may not be receiving agents thought to inhibit or induce the cytochrome p450 isoenzyme CYP3A4.
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Behandeling
- Toewijzing: NVT
- Interventioneel model: Opdracht voor een enkele groep
- Masker: Geen (open label)
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
---|---|
Experimenteel: 1
DMS 612 on day 1 and 2 with doses starting at 3.5mg/m2 to 18.5mg/m2 every 21 days until MTD is reached
|
DMS 612 on day 1 and 2 with doses starting at 3.5mg/m2 to 18.5mg/m2 every 21 days until MTD is reached
|
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
---|---|---|
Determine the Maximum Tolerated Dose
Tijdsspanne: End of Cycle 1
|
Number of DLTs in on a given dose level.
|
End of Cycle 1
|
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
---|---|---|
Evaluate non-dose limiting toxicity
Tijdsspanne: Treatment Completion
|
Number of overall toxicities on the study.
|
Treatment Completion
|
PK
Tijdsspanne: Collection of Samples
|
Drug level in blood
|
Collection of Samples
|
Anti-tumor Effects
Tijdsspanne: Disease Progression
|
Proportion of patients whose tumors shrunk after therapy
|
Disease Progression
|
Medewerkers en onderzoekers
Sponsor
Publicaties en nuttige links
Algemene publicaties
- Bishop JB, Wassom JS. Toxicological review of busulfan (Myleran). Mutat Res. 1986 Jul;168(1):15-45. doi: 10.1016/0165-1110(86)90020-5.
- Cangiano T, Liao J, Naitoh J, Dorey F, Figlin R, Belldegrun A. Sarcomatoid renal cell carcinoma: biologic behavior, prognosis, and response to combined surgical resection and immunotherapy. J Clin Oncol. 1999 Feb;17(2):523-8. doi: 10.1200/JCO.1999.17.2.523.
- Escudier B, Pluzanska A, Koralewski P, Ravaud A, Bracarda S, Szczylik C, Chevreau C, Filipek M, Melichar B, Bajetta E, Gorbunova V, Bay JO, Bodrogi I, Jagiello-Gruszfeld A, Moore N; AVOREN Trial investigators. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet. 2007 Dec 22;370(9605):2103-11. doi: 10.1016/S0140-6736(07)61904-7.
Studie record data
Bestudeer belangrijke data
Studie start
Primaire voltooiing (Werkelijk)
Studie voltooiing (Werkelijk)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Schatting)
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Trefwoorden
Aanvullende relevante MeSH-voorwaarden
- Ziekten van het spijsverteringsstelsel
- Ziekten van het immuunsysteem
- Neoplasmata per histologisch type
- Neoplasmata
- Lymfoproliferatieve aandoeningen
- Lymfatische ziekten
- Immunoproliferatieve aandoeningen
- Urologische neoplasmata
- Urogenitale neoplasmata
- Neoplasmata per site
- Nier Ziekten
- Urologische ziekten
- Adenocarcinoom
- Carcinoom
- Neoplasmata, glandulair en epitheel
- Gastro-intestinale neoplasmata
- Neoplasmata van het spijsverteringsstelsel
- Gastro-intestinale aandoeningen
- Nierneoplasmata
- Colon Ziekten
- Darmziekten
- Intestinale neoplasmata
- Colorectale neoplasmata
- Lymfoom
- Carcinoom, niercel
- Lymfoom, non-Hodgkin
- Koloniale neoplasmata
Andere studie-ID-nummers
- 090111
- 09-C-0111
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .
Klinische onderzoeken op Niercelcarcinoom
-
Peking University People's HospitalOnbekendNatural Killer Cell-gemedieerde immuniteitChina
-
Postgraduate Institute of Medical Education and...VoltooidType 1 HEPATO RENAL SYNDROOM (HRS)Indië
-
Alliance for Clinical Trials in OncologyNational Cancer Institute (NCI); NovartisActief, niet wervendRefractaire Hurthle Cell-schildklierkankerVerenigde Staten
-
Hospices Civils de LyonWervingKwaadaardige tumoren als Chordoma, Adenoid Cystic Carcinoma en SarcoomFrankrijk
-
Hadassah Medical OrganizationOnbekendNatural Killer Cell-deficiëntie, familiaal geïsoleerdIsraël
-
Bristol-Myers SquibbVoltooidTrombose | Nierfunctiestoornis | Factor XI | ESRD (End-Stage Renal Disease)Verenigde Staten
-
Assistance Publique - Hôpitaux de ParisNog niet aan het werven
-
Bing HanVoltooidPure Red Cell Aplasia, verworvenChina
-
Peking University First HospitalWervingNiercelcarcinoom, Clear Cell, SomatischChina
-
National Institute of Diabetes and Digestive and...WervingSchildklierkanker | Papillaire schildklierkanker | Hurthle Cell-schildklierkanker | Tall Cell Variant Schildklierkanker | Folliculaire schildklierkankerVerenigde Staten
Klinische onderzoeken op DMS 612
-
Hoffmann-La RocheVoltooidDiabetes mellitus, type 1Verenigde Staten
-
Sinew Pharma Inc.BeëindigdNASH - Niet-alcoholische steatohepatitisTaiwan
-
United Biomedical Inc., AsiaVaxxinity, Inc.Voltooid
-
Vaxxinity, Inc.Diagnósticos da América S/A (DASA)IngetrokkenCovid-19 | SARS-CoV-2 | Coronavirus
-
United Biomedical Inc., AsiaVaxxinity, Inc.Beëindigd
-
United Biomedical Inc., AsiaIngetrokken
-
Medicines for Malaria VentureRichmond Pharmacology LimitedVoltooid
-
United Biomedical Inc., AsiaVaxxinity, Inc.Voltooid
-
Centre Hospitalier Universitaire, AmiensVoltooidArtroplastiek | Duur van het verblijfFrankrijk
-
Medtronic BRCOnbekendHartfalenVerenigd Koninkrijk